| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
CCR2 modulates inflammatory and metabolic effects of high-fat feeding.
|
J Clin Invest
|
2005
|
10.44
|
|
2
|
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
|
N Engl J Med
|
2012
|
9.69
|
|
3
|
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
|
N Engl J Med
|
2010
|
8.77
|
|
4
|
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
|
Blood
|
2010
|
4.33
|
|
5
|
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
|
Cancer Cell
|
2006
|
3.20
|
|
6
|
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
|
Haematologica
|
2013
|
1.67
|
|
7
|
Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.
|
J Immunol
|
2005
|
1.49
|
|
8
|
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
|
J Immunol
|
2010
|
1.47
|
|
9
|
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
|
Blood
|
2010
|
1.42
|
|
10
|
Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
|
Mol Cancer Ther
|
2010
|
1.21
|
|
11
|
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.
|
Clin Cancer Res
|
2007
|
1.20
|
|
12
|
Severe retinal degeneration associated with disruption of semaphorin 4A.
|
Invest Ophthalmol Vis Sci
|
2004
|
1.08
|
|
13
|
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
|
Mol Cancer Ther
|
2009
|
1.00
|
|
14
|
Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab.
|
Cancer Biol Ther
|
2006
|
0.97
|
|
15
|
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
|
Br J Haematol
|
2013
|
0.95
|
|
16
|
Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
|
Bioorg Med Chem Lett
|
2010
|
0.95
|
|
17
|
Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
|
Drug Metab Dispos
|
2007
|
0.93
|
|
18
|
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
|
Neoplasia
|
2010
|
0.93
|
|
19
|
Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
|
J Invest Dermatol
|
2011
|
0.92
|
|
20
|
Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
|
Clin Cancer Res
|
2009
|
0.88
|
|
21
|
Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.
|
Bioorg Med Chem Lett
|
2011
|
0.84
|
|
22
|
Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
|
J Pharmacol Exp Ther
|
2011
|
0.82
|
|
23
|
Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.
|
Bioorg Med Chem Lett
|
2007
|
0.76
|
|
24
|
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
|
J Med Chem
|
2007
|
0.75
|
|
25
|
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.
|
Bioorg Med Chem Lett
|
2007
|
0.75
|